ReviewVascular medicine (London, England)2021
Catheter-directed thrombolysis for deep vein thrombosis: 2021 update.
Review in Vascular medicine (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 49 citations in OpenAlex.
- Predictors of Clinical Outcomes of Pharmacomechanical Catheter-Directed Thrombolysis for Acute Iliofemoral Deep Vein Thrombosis: Analysis of a Multicenter Randomized Trial.Journal of vascular and interventional radiology : JVIR · 2022Trial
- Complement Factor H as a Novel Predictive Biomarker for Deep Vein Thrombosis Recurrence: A Prospective Cohort Study.Journal of thrombosis and thrombolysis · 2026Article
- When Cancer Clots: An Extensive Radiologic Analysis of Cancer-Associated Thromboembolism.Cancers · 2026Review
- Association of serum inflammatory factors and hematologic parameters with lower limb deep vein thrombosis in neurocritical patients: A retrospective cohort study.Journal of medical biochemistry · 2026Article
- Pulse-spray catheter-directed thrombolysis with monteplase for IVC filter-associated thrombosis after massive pulmonary embolism requiring VA-ECMO: a case report.European heart journal. Case reports · 2026Article
- Urokinase redux: route, compartment, access, and pharmacological evolution from native urokinase to recombinant prourokinase.Frontiers in cardiovascular medicine · 2026Review
- Percutaneous mechanical thrombectomy combined with catheter-directed thrombolysis improves clinical outcomes in subacute lower extremity deep vein thrombosis.American journal of translational research · 2026Article
- Post-Thrombotic Syndrome: Pathophysiology, Clinical Implications, and Advances in Management.Health science reports · 2025Article
- Prevention of the Postthrombotic Syndrome: Where Do We Stand?Seminars in interventional radiology · 2025Review
- Article
- Thrombolytic therapy of human black hair and Au drug-loaded nanocapsules in vivo and in vitro based on near infrared II laser response.Journal of materials science. Materials in medicine · 2025Article
- Residual popliteal vein thrombosis after endovascular treatment of mixed-type lower extremity deep vein thrombosis is relevant to post-thrombotic syndrome.Journal of vascular surgery. Venous and lymphatic disorders · 2025Article
- Effect of different balloon pressure band compression regimens on thrombolysis and lower limb venous blood flow velocity in patients undergoing anterograde thrombolysis via the superficial dorsalis pedis vein.Thrombosis journal · 2025Article
- Natural active herbal monomers for the treatment of thromboembolic diseases: a review.Frontiers in pharmacology · 2025Review
- Sonothrombolysis Using Microfluidically Produced Microbubbles in a Murine Model of Deep Vein Thrombosis.Annals of biomedical engineering · 2025Article
- Impact of catheter-directed thrombolysis access approach on entire-limb deep vein thrombosis: a focus on inflow patency.Frontiers in cardiovascular medicine · 2025Article
- Early Thrombus Removal for Acute Lower Extremity Deep Vein Thrombosis: Update on Inclusion, Technical Aspects, and Postprocedural Management.Cardiovascular and interventional radiology · 2024Review
- Targeting Fibrinolytic Inhibition for Venous Thromboembolism Treatment: Overview of an Emerging Therapeutic Approach.Circulation · 2024Review
- Analysis of risk factors for post-thrombotic syndrome after thrombolysis therapy for acute deep venous thrombosis of lower extremities.International journal of cardiology. Cardiovascular risk and prevention · 2024Article
- A mapping review of Pacific Vascular Symposium 6 initiatives.Journal of vascular surgery. Venous and lymphatic disorders · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
Catheter-directed thrombolysis (CDT) has been utilized as an adjunct to anticoagulant therapy in selected patients with deep vein thrombosis (DVT) for approximately 30 years. CDT used to be limited to patients with DVT causing acute limb threat and those exhibiting failure of initial anticoagulation, but has expanded over time. Randomized trials evaluating the first-line use of CDT for proximal DVT have demonstrated that CDT does not produce a major reduction in the occurrence of post-thrombotic syndrome (PTS) and that it is poorly suited for elderly patients and those with limited thrombus extent or major risk factors for bleeding. However, CDT does offer selected patients with acute iliofemoral DVT improvement in reducing early DVT symptoms, in achieving reduction in PTS severity, and in producing an improvement in health-related quality of life (QOL). Clinical practice guidelines from medical and surgical societies are now largely aligned with the randomized trial results. This review offers the reader an update on the results of recently completed clinical trials, and additional guidance on appropriate selection of patients with DVT for catheter-directed thrombolytic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.